ZS Pharma's ion trap candidate jumps next Ph III hurdle
This article was originally published in Scrip
Executive Summary
ZS Pharma's candidate for hyperkalemia, ZS-9, has met the pre-specified endpoint of the 12-day extended treatment phase of its pivotal Phase III trial.